688758.SHG Suzhou Sepax Technologies Co Ltd Ordinary Shares - Class A
- Market cap
- CNY 10.1B
- P/E
- 50.4x
- P/B
- 6.89x
- ROE
- 15.9%
- Dividend yield
- 0.28%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 688758.SHG undervalued?
Graham numberThe Graham number of Suzhou Sepax Technologies Co Ltd Ordinary Shares - Class A cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Suzhou Sepax Technologies Co Ltd Ordinary Shares - Class A fundamental analysis
No fundamental analysis for Suzhou Sepax Technologies Co Ltd Ordinary Shares - Class A yet.
Suzhou Sepax Technologies Co Ltd Ordinary Shares - Class A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Suzhou Sepax Technologies Co Ltd Ordinary Shares - Class A
Suzhou Sepax Technologies Co., Ltd., a high-tech company, engages on the research, development, production, and sale of liquid chromatography materials and technologies worldwide. Its products are chromatographic columns and chromatographic fillers used in the analysis, detection, separation and purification of biological macromolecule drugs and small molecule chemical drugs. The company's analytical chromatography products are used for analytical testing in drug development…
Full company profileSuzhou Sepax Technologies Co Ltd Ordinary Shares - Class A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Suzhou Sepax Technologies Co Ltd Ordinary Shares - Class A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 213M | 245M | 315M | 403M | 559M |
| Gross Profit | 162M | 175M | 224M | 288M | 421M |
| Operating Income | 44.4M | 54.4M | 97.5M | 141M | 246M |
| EBITDA | 69.9M | 81.8M | 122M | 167M | 255M |
| Net Income | 47.1M | 52.5M | 85.2M | 127M | 221M |
| EPS | 0.13 | 0.14 | 0.20 | 0.30 | 0.53 |
| Balance Sheet | |||||
| Total Assets | 1.05B | 1.10B | 1.18B | 1.45B | 1.59B |
| Total Liabilities | 101M | 96.2M | 84.3M | 90.3M | 187M |
| Shareholders' Equity | 941M | 998M | 1.09B | 1.35B | 1.39B |
| Cash & Short-term Investments | 335M | 259M | 103M | 184M | 213M |
| Cash Flow | |||||
| Operating Cash Flow | 28.5M | 43.4M | 66.0M | 103M | - |
| Capital Expenditure | 48.7M | 19.1M | 13.5M | 14.0M | 62.3M |
| Free Cash Flow | -20.2M | 24.2M | 52.5M | 88.5M | 110M |
| Ratios | |||||
| ROE | 5.0% | 5.3% | 7.8% | 9.4% | 15.9% |
| ROA | 4.5% | 4.8% | 7.2% | 8.7% | 14.0% |
| Net Profit Margin | 22.2% | 21.4% | 27.0% | 31.4% | 39.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Suzhou Sepax Technologies Co Ltd Ordinary Shares - Class A dividends
- Dividend yield
- 0.28%
- Forward dividend
- 0.10 CNY
- Payout ratio
- 22.1%
- Ex-dividend date
- Jul 22, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 27.9M | 0.07 | 22.1% |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | CNY 51.5K | 0.00 | 0.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Suzhou Sepax Technologies Co Ltd Ordinary Shares - Class A
- Insiders 59.64%
- Institutions 12.67%
- Public & others 27.69%
- Shares outstanding 416M
- Free float 156M
Suzhou Sepax Technologies Co Ltd Ordinary Shares - Class A company profile
- Company name
- Suzhou Sepax Technologies Co Ltd Ordinary Shares - Class A
- Ticker
- 688758.SHG
- Exchange
- Shanghai Stock Exchange
- Sector
- Basic Materials
- Industry
- Chemicals
- Employees
- 417
- Fiscal year end
- December
- Address
- Suzhou Saifen Technology R&D Office Building, Suzhou, China, 215123
- Phone
- 86 40 0636 8880
- Website
- sepax-tech.com.cn
About Suzhou Sepax Technologies Co Ltd Ordinary Shares - Class A
Suzhou Sepax Technologies Co., Ltd., a high-tech company, engages on the research, development, production, and sale of liquid chromatography materials and technologies worldwide. Its products are chromatographic columns and chromatographic fillers used in the analysis, detection, separation and purification of biological macromolecule drugs and small molecule chemical drugs. The company's analytical chromatography products are used for analytical testing in drug development and quality inspection. Suzhou Sepax Technologies Co., Ltd. was founded in 2002 and is headquartered in Suzhou, China.
Suzhou Sepax Technologies Co Ltd Ordinary Shares - Class A management
10- Dr. Xueying HuangGM & Chairman of the Board · born 1967
- Mr. Zhu ZhaojinChief Financial Officer · born 1978
- Mr. Ni HaoDirector and GM of US-based Ceftrix Biotech & Ceftrix Biotech · born 1974
- Ms. Wang ZhongleiBoard Secretary · born 1996
- Mr. Sun KeDeputy General Manager · born 1974
- Xi Ya WangAccounting Supervisor
- Dr. Huiming MaoTechnical Director · born 1979
- Dr. Hongyu WangGlobal Chief Quality Officer · born 1964
- Dr. Mathew GeorgeDirector of R&D Department · born 1967
- Mr. Xiaotao ZhouDirector of Operations of US Division · born 1975